Swiss pharmaceutical giant Novartis has recalled some of its Sandimmune and Neoral blister packs in the US over a packaging issue.

According to the company, the recall will affect Sandimmune (cyclosporine capsules, USP) 100mg soft gelatin capsules 30-count pack and liquid-filled single capsule blister packs.

It also covers Neoral (cyclosporine capsules, USP) MODIFIED 100mg soft gelatin capsules 30 count pack and liquid-filled single capsule blister packs.

The company identified that the 30-count blister packs distributed in the US failed to meet child-resistant packaging guidelines.

In response to this, the company issued a Consumer Product Safety Commission (CPSC) approved corrective action plan.

The packaging problem could pose harm if a child opened the pack and swallowed the medicine. Patients have been advised to keep the packs out of children’s reach to ensure safety.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a statement, Novartis said: “At Novartis, we take our responsibility for consumer safety very seriously.

“As soon as we became aware that these blister packs do not meet federal standards for child-resistant packaging, we promptly notified the CPSC and the Food and Drug Administration (FDA) and have been working closely with the CPSC to remedy the packaging issue and ensure continuity of treatment.

“An appropriate solution was identified in cooperation with the CPSC.

“There are no quality or efficacy issues with the medicines for their intended use.”

To avoid shortage of the drug, the company is providing resealable child-resistant pouches to those affected.